Portola Pharmaceuticals, Inc.’s $258.8 Million Follow-On Offering

Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering of common stock by Portola Pharmaceuticals, Inc.

The common stock is listed on The Nasdaq Global Select Market under the symbol “PTLA.”

Based in South San Francisco, California, Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases.

Goldman Sachs & Co. LLC, Citigroup, Cowen, William Blair and Oppenheimer & Co. acted as underwriter on the deal.

The Davis Polk corporate team included partners Bruce K. Dallas (Picture) and Emily Roberts and associates Dongbiao Shen and Daniel Fox. Partner Rachel D. Kleinberg and associate Tomislava Dragicevic provided tax advice. Associates Michael V. Policastro and Jennifer Leather provided intellectual property and technology advice.

Involved fees earner: Bruce Dallas – Davis Polk & Wardwell; Tomislava Dragicevic – Davis Polk & Wardwell; Daniel Fox – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Jennifer Leather – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Dongbiao Shen – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Citigroup Inc.; Cowen Inc.; Goldman Sachs & Co.; Oppenheimer & Co; William Blair & Company, L.L.C.;


Author: Ambrogio Visconti